Design and Evaluate 12 Week Group Therapy Intervention for HIV+ Methamphetamine Users and Deliver It Within an HIV/AIDS Primary Care Setting. - 1

This study is not yet open for participant recruitment.

Verified by National Institute on Drug Abuse (NIDA), November 2005

Sponsors and Collaborators:	National Institute on Drug Abuse (NIDA) University of California, Los Angeles
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00249678

Purpose

The purpose of this study is...to assess whether placing a substance abuse intervention for HIV+ methamphetamine users within an HIV medical care setting improves rates of follow-up on referral to treatment by primary care physicians; reduces drug use and sexual risk behaviors more than treatment-as-usual; and increases rates of adherence to HIV medication regimens.

Condition	Intervention	Phase
Behavior Therapy Methamphetamine	Behavioral: Behavior Therapy	Phase II

MedlinePlus related topics: AIDS Methamphetamine

Drug Information available for: Amphetamine Methamphetamine

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment
Official Title:	Behavioral Therapy Development for Methamphetamine Abuse

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Craving
Medication compliance
Addiction severity
Psychiatric interview
Sex-risk behavior

Secondary Outcome Measures:

Depression
Quality of Life

Estimated Enrollment:

Eligibility

Ages Eligible for Study:	18 Years to 65 Years
Genders Eligible for Study:	Male
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

HIV-seropositive, GBM receiving medical treatment for HIV for at least 30 days prior to signing informed consent at the UCLA CARE clinic, aged 18-65
Willing to give informed consent and comply with study procedures;
Willing to provide consent to contact treating physicians and pharmacies to assess adherence to HIV medications;
Diagnosed with current methamphetamine abuse as determined by MINI; and
Interested in seeking treatment for their methamphetamine abuse and in participating in this research project.

Exclusion Criteria:

Unwilling to give, or withdrawal of, informed consent;
Inability to understand nature of study;
A psychiatric condition that, in the principal investigator's judgment, warrants additional intervention to ensure participant safety (e.g., meets DSM-IV-TR criteria for current bipolar disorder or a psychotic disorder);
Current suicidal ideation or suicide attempt within the past 3 months; and
Concurrent dependence on opiates, alcohol, or benzodiazepines as determined by MINI.
Total lack of any type of healthcare coverage. These potential participants will be given low-fee treatment referrals.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00249678

Locations

United States, California
UCLA CARE Clinic
Los Angeles, California, United States, 90035
UCLA Medical Center
Los Angeles, California, United States, 90024
UCLA, Integrated Substance Abuse Programs
Los Angeles, California, United States, 90024

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

University of California, Los Angeles

Investigators

Principal Investigator:

James Peck, Other

University of California, Los Angeles

More Information

Study ID Numbers:	NIDA-18075-1, R21-18075-1
Study First Received:	November 3, 2005
Last Updated:	November 3, 2005
ClinicalTrials.gov Identifier:	NCT00249678
Health Authority:	United States: Federal Government/HHS/NIH/NIDA

Study placed in the following topic categories:

Methamphetamine
Dopamine
HIV Infections
Acquired Immunodeficiency Syndrome
Amphetamine

Additional relevant MeSH terms:

Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Adrenergic Agents
Sympathomimetics
Adrenergic Uptake Inhibitors
Physiological Effects of Drugs

Central Nervous System Stimulants
Pharmacologic Actions
Autonomic Agents
Therapeutic Uses
Dopamine Agents
Peripheral Nervous System Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on January 14, 2009